Improving the Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy

References

• Koski CL , BaumgartenM, MagderLSet al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy . J. Neurol. Sci.277 ( 1–2 ), 1 – 8 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Lunn MP , ManjiH, ChoudharyPP, HughesRA, ThomasPK . Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England . J. Neurol. Neurosurg. Psychiatry66 ( 5 ), 677 – 680 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Iijima M , KoikeH, HattoriNet al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population . J. Neurol. Neurosurg. Psychiatry79 ( 9 ), 1040 – 1043 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• McLeod JG , PollardJD, MacaskillP, MohamedA, SpringP, KhuranaV . Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia . Ann. Neurol.46 ( 6 ), 910 – 913 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Chiò A , CocitoD, BottacchiEet al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy . J. Neurol. Neurosurg. Psychiatry78 ( 12 ), 1349 – 1353 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Rajabally YA , SimpsonBS, BeriS, BankartJ, GosalakkalJA . Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population . Muscle Nerve39 ( 4 ), 432 – 438 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Laughlin RS , DyckPJ, MeltonLJ, LeibsonC, RansomJ, DyckPJ . Incidence and prevalence of CIDP and the association of diabetes mellitus . Neurology73 ( 1 ), 39 – 45 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Joint Task Force of the EFNS and the PNS . European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision . J. Peripher. Nerv. Syst.15 ( 1 ), 1 – 9 ( 2010 ).
   Web of Science ®Google Scholar
• Mathey EK , ParkSB, HughesRAet al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype . J. Neurol. Neurosurg. Psychiatry86 ( 9 ), 973 – 985 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force . Neurology41 ( 5 ), 617 – 618 ( 1991 ).
   PubMed Web of Science ®Google Scholar
• Allen JA , LewisRA . CIDP diagnostic pitfalls and perception of treatment benefit . Neurology85 ( 6 ), 498 – 504 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Cornblath DR , GorsonKC, HughesRA, MerkiesIS . Observations on chronic inflammatory demyelinating polyneuropathy: a plea for a rigorous approach to diagnosis and treatment . J. Neurol. Sci.330 ( 1–2 ), 2 – 3 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ripellino P , FleetwoodT, CantelloR, ComiC . Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations . Autoimmune Dis.2014, 201657 ( 2014 ).
   PubMedGoogle Scholar
• Gorson KC , GoochCL . The (mis)diagnosis of CIDP: the high price of missing the mark . Neurology85 ( 6 ), 488 – 489 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Allen JA . Diagnosing CIDP: observations from our community. Challenges in identifying CIDP and predicting response to immunomodulatory treatment in real world patient populations . Peripheral Nerve Society Annual General Meeting . Quebec, Canada, 27 June–1 July 2015 .
   Google Scholar
• Viala K , MaisonobeT, StojkovicTet al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy . J. Peripher. Nerv. Syst.15 ( 1 ), 50 – 56 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Bouchard C , LacroixC, PlantéVet al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy . Neurology52 ( 3 ), 498 – 503 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Kobessho H , OishiK, HamaguchiH, KandaF . Elevation of cerebrospinal fluid protein in patients with diabetes mellitus is associated with duration of diabetes . Eur. Neurol.60 ( 3 ), 132 – 136 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Gorson KC , van SchaikIN, MerkiesISet al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice . J. Peripher. Nerv. Syst.15 ( 4 ), 326 – 333 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Rajabally YA , CassereauJ, RobbeA, NicolasG . Disease status in chronic inflammatory demyelinating polyneuropathy: inter-centre comparative analysis and correlates . Eur. J. Neurol.22 ( 11 ), 1469 – 1473 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hughes RA , GorsonKC, CrosDet al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy . Neurology74 ( 8 ), 651 – 657 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• RMC Trial Group . Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study . Lancet Neurol.8 ( 2 ), 158 – 164 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Hughes RA , DonofrioP, BrilVet al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial . Lancet Neurol.7 ( 2 ), 136 – 144 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Cocito D , PaolassoI, AntoniniGet al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy . Eur. J. Neurol.17 ( 2 ), 289 – 294 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Sharma KR , CrossJ, FarronayO, AyyarDR, ShebertRT, BradleyWG . Demyelinating neuropathy in diabetes mellitus . Arch. Neurol.59 ( 5 ), 758 – 765 ( 2002 ).
   PubMedGoogle Scholar
• Lozeron P , NahumL, LacroixC, RopertA, GuglielmiJM, SaidG . Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients . J. Neurol.249 ( 5 ), 569 – 575 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Chiò A , PlanoF, CalvoA, LeoneM, MutaniR, CocitoD . Piemonte and Valle D’Aosta Registry for CIDP (PARCIDP). Comorbidity between CIDP and diabetes mellitus: only a matter of chance?Eur. J. Neurol.16 ( 6 ), 752 – 754 ( 2009 ).
   PubMedGoogle Scholar
• Dyck PJ , AlbersJW, AndersenHet al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity . Diabetes Metab. Res. Rev.27 ( 7 ), 620 – 628 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Behse F , BuchthalF, CarlsenF . Nerve biopsy and conduction studies in diabetic neuropathy . J. Neurol. Neurosurg. Psychiatry40 ( 11 ), 1072 – 1082 ( 1977 ).
   PubMed Web of Science ®Google Scholar
• Dunnigan SK , EbadiH, BreinerAet al. Conduction slowing in diabetic sensorimotor polyneuropathy . Diabetes Care36 ( 11 ), 3684 – 3690 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Dunnigan SK , EbadiH, BreinerAet al. The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes – an observational study . PLoS ONE9 ( 2 ), e89344 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Chan YC , AllenDC, FialhoD, MillsKR, HughesRA . Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy . J. Neurol. Neurosurg. Psychiatry77 ( 1 ), 114 – 116 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Cocito D , ChiòA, TavellaAet al. Treatment response and electrophysiological criteria in chronic inflammatory demyelinating polyneuropathy . Eur. J. Neurol.13 ( 6 ), 669 – 670 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Hahn AF , BoltonCF, ZochodneD, FeasbyTE . Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study . Brain119 ( Pt 4 ), 1067 – 1077 ( 1996 ).
   PubMedGoogle Scholar
• Mendell JR , BarohnRJ, FreimerMLet al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy . Neurology56 ( 4 ), 445 – 449 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Kuitwaard K , HahnAF, VermeulenM, VenanceSL, van DoornPA . Intravenous immunoglobulin response in treatment-naive chronic inflammatory demyelinating polyradiculoneuropathy . J. Neurol. Neurosurg. Psychiatry86 ( 12 ), 1331 – 1336 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hahn AF , BoltonCF, PillayNet al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study . Brain119 ( pt 4 ), 1055 – 1066 ( 1996 ).
   PubMedGoogle Scholar
• Abraham A , BreinerA, KatzbergHD, LovblomLE, PerkinsBA, BrilV . Treatment responsiveness in CIDP patients with diabetes is associated with unique electrophysiological characteristics, and not with common criteria for CIDP . Expert Rev. Clin. Immunol.11 ( 4 ), 537 – 546 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mygland A , MonstadP, VedelerC . Onset and course of chronic inflammatory demyelinating polyneuropathy . Muscle Nerve31 ( 5 ), 589 – 593 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Simmons Z , AlbersJW, BrombergMB, FeldmanEL . Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy . Neurology43 ( 11 ), 2202 – 2209 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Gorson KC , AllamG, RopperAH . Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy . Neurology48 ( 2 ), 321 – 328 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Kuwabara S , OgawaraK, MisawaS, MoriM, HattoriT . Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy . J. Neurol. Neurosurg. Psychiatry72 ( 1 ), 37 – 42 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Bril V , BanachM, DalakasMCet al. Electrophysiologic correlations with clinical outcomes in CIDP . Muscle Nerve42 ( 4 ), 492 – 497 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Bril V . Treatment responsiveness in CIDP patients with diabetes. Challenges in identifying CIDP and predicting response to immunomodulatory treatment in real world patient populations . Peripheral Nerve Society Annual General Meeting . Quebec, Canada, 27 June–1 July 2015 .
   Google Scholar
• Van den Bergh PY , PiéretF . Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy . Muscle Nerve29 ( 4 ), 565 – 574 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• van Nes SI , FaberCG, MerkiesIS . Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials . J. Peripher. Nerv. Syst.13 ( 2 ), 136 – 147 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Vanhoutte EK , FaberCG, MerkiesIS . PeriNomS study group. 196th ENMC international workshop: outcome measures in inflammatory peripheral neuropathies 8–10 February 2013, Naarden, The Netherlands . Neuromuscul. Disord.23 ( 11 ), 924 – 933 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• van Nes SI , VanhoutteEK, van DoornPAet al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies . Neurology76 ( 4 ), 337 – 345 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Draak TH , VanhoutteEK, van NesSIet al. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness . Neurology83 ( 23 ), 2124 – 2132 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Vanhoutte EK , LatovN, DengCet al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG-the ICE study . Eur. J. Neurol.20 ( 5 ), 748 – 755 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Rajabally YA , NarasimhanM . Jamar hand-held grip dynamometry in chronic inflammatory demyelinating polyneuropathy . J. Neurol. Sci.325 ( 1–2 ), 36 – 38 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Draak TH , PruppersMH, van NesSIet al. Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar . J. Peripher. Nerv. Syst.20 ( 3 ), 269 – 276 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Comi C , OsioM, FerrettiMet al. Defective Fas-mediated T-cell apoptosis predicts acute onset CIDP . J. Peripher. Nerv. Syst.14 ( 2 ), 101 – 106 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Comi C . Fas-mediated T-cell apoptosis in chronic inflammatory demyelinating polyneuropathy . J. Peripher. Nerv. Syst.16 ( Suppl. 1 ), 45 – 47 ( 2011 ).
   PubMedGoogle Scholar
• Sung JY , TaniJ, ParkSB, KiernanMC, LinCS . Early identification of ‘acute-onset’ chronic inflammatory demyelinating polyneuropathy . Brain137 ( Pt 8 ), 2155 – 2163 ( 2014 ).
   PubMedGoogle Scholar
• Querol L , Nogales-GadeaG, Rojas-GarciaRet al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg . Neurology82 ( 10 ), 879 – 886 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kuwabara S , IsoseS, MoriMet al. Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy . J. Neurol. Neurosurg. Psychiatry86 ( 10 ), 1054 – 1059 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Querol L , Nogales-GadeaG, Rojas-GarciaRet al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy . Ann. Neurol.73 ( 3 ), 370 – 380 ( 2013 ).
   PubMed Web of Science ®Google Scholar